ABIVAX Société Anonyme (NASDAQ:ABVX) Receives “Market Outperform” Rating from JMP Securities

JMP Securities reiterated their market outperform rating on shares of ABIVAX Société Anonyme (NASDAQ:ABVX) in a report released on Friday,Benzinga reports. JMP Securities currently has a $33.00 price objective on the stock.

Separately, Citizens Jmp raised ABIVAX Société Anonyme to a “strong-buy” rating in a research note on Wednesday, December 4th. One investment analyst has rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, ABIVAX Société Anonyme currently has a consensus rating of “Buy” and a consensus target price of $38.67.

ABIVAX Société Anonyme Stock Down 4.5 %

NASDAQ:ABVX opened at $6.38 on Friday. The stock’s 50-day simple moving average is $8.38 and its 200 day simple moving average is $10.42. ABIVAX Société Anonyme has a twelve month low of $6.26 and a twelve month high of $17.02.

Hedge Funds Weigh In On ABIVAX Société Anonyme

Several large investors have recently bought and sold shares of ABVX. GAMMA Investing LLC bought a new position in ABIVAX Société Anonyme in the fourth quarter valued at about $29,000. BNP Paribas Financial Markets raised its position in ABIVAX Société Anonyme by 82.6% in the third quarter. BNP Paribas Financial Markets now owns 13,044 shares of the company’s stock valued at $150,000 after purchasing an additional 5,900 shares during the last quarter. Walleye Capital LLC raised its position in ABIVAX Société Anonyme by 45.8% in the third quarter. Walleye Capital LLC now owns 257,417 shares of the company’s stock valued at $2,965,000 after purchasing an additional 80,807 shares during the last quarter. abrdn plc raised its position in ABIVAX Société Anonyme by 167.7% in the third quarter. abrdn plc now owns 316,431 shares of the company’s stock valued at $3,645,000 after purchasing an additional 198,225 shares during the last quarter. Finally, Point72 Asset Management L.P. raised its position in shares of ABIVAX Société Anonyme by 28.2% during the third quarter. Point72 Asset Management L.P. now owns 542,900 shares of the company’s stock worth $6,254,000 after acquiring an additional 119,300 shares during the last quarter. 47.91% of the stock is currently owned by institutional investors.

About ABIVAX Société Anonyme

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults.